Recombinant Human Relaxin for the Treatment of Decompensated CHF

• Status: Terminated
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
• Treatments: Methocarbamol

Criteria

Inclusion Criteria:

• Hospitalization

• Decompensated chronic CHF (NYHA Class III-IV)

• LVEF < 35%

• PCWP > 22 mmHg

• CI < 2.3 L/min/m2

Exclusion Criteria:

• Acute CHF

• Acute coronary syndrome

• Hypotension or shock

• Recent stroke

• Allergy or sensitivity to test agents

• Significant confounding conditions or medications